Drug-Eluting Stent Shows Similar Patency Results as Prosthetic Bypass in Patients with Femoropopliteal Occlusion in a Randomized Trial

Show full item record



Permalink

http://hdl.handle.net/10138/305724

Citation

Björkman , P , Auvinen , T , Hakovirta , H , Romsi , P , Turtiainen , J , Manninen , H & Venermo , M 2018 , ' Drug-Eluting Stent Shows Similar Patency Results as Prosthetic Bypass in Patients with Femoropopliteal Occlusion in a Randomized Trial ' , Annals of Vascular Surgery , vol. 53 , pp. 165-170 . https://doi.org/10.1016/j.avsg.2018.04.014

Title: Drug-Eluting Stent Shows Similar Patency Results as Prosthetic Bypass in Patients with Femoropopliteal Occlusion in a Randomized Trial
Author: Björkman, Patrick; Auvinen, Tommi; Hakovirta, Harri; Romsi, Pekka; Turtiainen, Johanna; Manninen, Hannu; Venermo, Maarit
Contributor: University of Helsinki, Verisuonikirurgian yksikkö
University of Helsinki, Verisuonikirurgian yksikkö
Date: 2018-11
Language: eng
Number of pages: 6
Belongs to series: Annals of Vascular Surgery
ISSN: 0890-5096
URI: http://hdl.handle.net/10138/305724
Abstract: Background: Claudication and critical limb threatening ischemia are significant causes of mortality in the elderly. The gold standard of superficial femoral artery (SFA) revascularization is thus far considered to be the femoropopliteal bypass. The aim of this study was to compare mid-term patency between drug-eluting stents (DESs) and prosthetic bypass grafts (BSX). Studies have reported comparable results for both the methods. Methods: Forty-six patients with claudication or rest pain due to a 5-25 cm SFA occlusion were randomized between DES and BSX groups. The follow-up period was 24 months, and the primary outcome measure was overall patency. Secondary outcome measures were primary and primary assisted patency, change in ankle-brachial index (ABI), and amputation-free survival. Results: Forty-one patients were eventually analyzed. Six-month secondary patency was 91% (DES) versus 83% (BSX) (P = 0.450). The corresponding numbers at 12 months in the DES and BSX groups were 74% and 80% (P = 0.750), respectively. At 24 months, the respective numbers were 56% and 71% (P = 0.830). There were no statistically significant differences in primary or assisted primary patency at 1, 6, or 12 months. Conclusion: There were no demonstrable differences in patency rates or clinical outcomes such as ABI or major amputations between DES and BSX. Although underpowered, the results suggest noninferiority of the DES compared with prosthetic bypass surgery.
Subject: FEMORAL-POPLITEAL BYPASS
INTER-SOCIETY CONSENSUS
CRITICAL LIMB ISCHEMIA
ARTERY DISEASE
ANGIOPLASTY
PTFE
3126 Surgery, anesthesiology, intensive care, radiology
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0890509618304308_main.pdf 393.2Kb PDF View/Open
Drug_eluting_st ... _in_a_randomized_trial.pdf 974.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record